Quick Answer
RenovoRx, Inc. reported Total Revenue of $1.12 million for fiscal year 2025.
RenovoRx, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $1.12M +2511.6% |
$43.0K | — | — | — | — |
| Net Income | -$11.17M -26.7% |
-$8.81M +13.9% |
-$10.23M -3.5% |
-$9.89M -56.4% |
-$6.32M -66.5% |
-$3.80M |
| Diluted EPS | -$0.32 +20.0% |
-$0.40 +59.6% |
-$0.99 +9.2% |
-$1.09 | — | — |
| Total Assets | $8.10M -0.3% |
$8.12M +453.8% |
$1.47M -79.8% |
$7.26M -55.4% |
$16.29M +750.9% |
$1.91M |
| Cash and Equivalents | $7.02M -1.8% |
$7.15M +509.9% |
$1.17M -73.3% |
$4.39M -71.1% |
$15.19M +746.4% |
$1.79M |
| Stockholders Equity | $5.42M +21.1% |
$4.48M +49.3% |
$3.00M -51.3% |
$6.16M -59.8% |
$15.35M +204.7% |
-$14.66M -34.1% |
| R&D Expense | $6.27M +4.0% |
$6.03M +6.3% |
$5.67M +31.8% |
$4.30M +41.5% |
$3.04M +27.4% |
$2.39M |
| Operating Income | -$12.51M -14.0% |
-$10.97M +3.7% |
-$11.40M -14.5% |
-$9.95M -75.5% |
-$5.67M -77.0% |
-$3.20M |
| Gross Profit | $796.0K +1751.2% |
$43.0K | — | — | — | — |
| Shares Outstanding | 36.61M +52.3% |
24.03M +124.8% |
10.69M +17.5% |
9.10M +1.8% |
8.93M +300.1% |
2.23M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $266.0K | — | -37.0% |
| Net Income | September 30, 2025 | -$2.91M | -17.8% | -0.6% |
| Diluted EPS | September 30, 2025 | -$0.08 | +20.0% | +0.0% |
| Total Assets | September 30, 2025 | $11.21M | +11.7% | -17.9% |
| Cash and Equivalents | September 30, 2025 | $10.04M | +5.0% | -18.4% |
| Stockholders Equity | September 30, 2025 | $8.08M | +14.2% | -24.1% |
| R&D Expense | September 30, 2025 | $1.69M | +2.1% | +18.2% |
| Operating Income | September 30, 2025 | -$3.20M | -13.2% | -19.5% |
| Gross Profit | September 30, 2025 | $213.0K | — | -21.1% |
| Shares Outstanding | September 30, 2025 | 36.65M | +52.7% | +0.0% |
- RenovoRx, Inc. reported Total Revenue of $1.12 million for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +2511.6% in Total Revenue compared to the prior fiscal year.
- RenovoRx, Inc. reported Net Income of -$11.17 million for fiscal year 2025.
- RenovoRx, Inc. showed a decrease of -26.7% in Net Income compared to the prior fiscal year.
- RenovoRx, Inc. reported Diluted EPS of $0.32 per share (loss) for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +20.0% in Diluted EPS compared to the prior fiscal year.
- RenovoRx, Inc. reported Total Assets of $8.10 million for fiscal year 2025.
- RenovoRx, Inc. showed a decrease of -0.3% in Total Assets compared to the prior fiscal year.
- RenovoRx, Inc. reported Cash and Equivalents of $7.02 million for fiscal year 2025.
- RenovoRx, Inc. showed a decrease of -1.8% in Cash and Equivalents compared to the prior fiscal year.
- RenovoRx, Inc. reported Stockholders Equity of $5.42 million for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +21.1% in Stockholders Equity compared to the prior fiscal year.
- RenovoRx, Inc. reported R&D Expense of $6.27 million for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- RenovoRx, Inc. reported Operating Income of -$12.51 million for fiscal year 2025.
- RenovoRx, Inc. showed a decrease of -14.0% in Operating Income compared to the prior fiscal year.
- RenovoRx, Inc. reported Gross Profit of $796.0 thousand for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +1751.2% in Gross Profit compared to the prior fiscal year.
- RenovoRx, Inc. reported Shares Outstanding of 36.61 million shares for fiscal year 2025.
- RenovoRx, Inc. showed an increase of +52.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: